Sanofi to Exit Diabetes Research
Scott Benner
“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history. As tough a choice as that is, we’re making that choice.”
The maker of the world’s top-selling insulin has given up on finding new diabetes drugs. which makes Lantus, said Monday it would stop investing in diabetes research after years of frustrated attempts to bring a fresh blockbuster to the market.
The decision is part of a broader strategic overhaul by new Chief Executive Paul Hudson, who hopes to reinvigorate growth at the French health-care giant by focusing on fewer, more specialized disease areas such as cancer—mirroring a move being made across the drug industry.
Read the entire article here
juicebox podcast
#1367 Glucagon Story: Laura
Source
Comment